Hangzhou Tigermed Consulting Reports FY Results
2024 Financial Report | BGI's profit fell by more than 80%, making it difficult to find the next outlet
The era of gold everywhere is over
Pharmacovigilance disintegrates CXO, what is the market concerned about?
It was only in December that the full-year forecast was lowered. What kind of medicine does Yakumin Biotech sell in gourds?
WuXi AppTec GAAP EPS of RMB 0.94, Revenue of RMB 10.67B
“Yemao” Tongze Healthcare's revenue growth in the third quarter was close to stagnation, and net profit fell 5.58% year on year | Financial News
Tongce Medical's revenue for the first three quarters was 2.85 billion yuan, up 2.12% year on year; net profit to mother was 512 million yuan, a decrease of 0.67% year on year.
There are not enough diet pills, Pharmacom announces another 60% increase in production capacity | Insight Research
Pharmaceutical Kangde announced today that its subsidiary Hequan Pharmaceutical will increase its peptide production capacity by 60%. At present, Hequan Pharmaceutical has begun a polypeptide production capacity expansion project for two production sites in Changzhou and Taixing. After the expansion is completed, Hequan Pharmaceutical will add multiple solid phase synthesis production lines for peptides. The new production capacity is expected to be put into use in December 2023. At that time, the volume of the peptide solid phase synthesis reactor will increase from the 20,000L originally planned to 32,000L. Previously, at the production site of Pharmaceutical Ming Kangde in Changzhou, WuXiTides put into operation two 2,000L polypeptide solid-phase synthesizers in April of this year, which means WuXiti
“Ate” 19 hospitals in one go, and Aier Ophthalmology went to the county
Aier Ophthalmology is already a “veteran” of industrial fund mergers and acquisitions. On September 21, Aier Ophthalmology announced that it plans to spend 860 million yuan to acquire some shares in a total of 19 ophthalmology hospitals, including Hainan Air and Zaozhuang Aier, held by 6 industrial investment funds. According to statistics from TradeWind01 (ID: TradeWind01), the total revenue of these 19 hospitals in 2022 and January to July 2023 could reach 523 million yuan and 379 million yuan respectively. Judging from the geographical location of the merger and acquisition targets, a total of 6 ophthalmology hospitals including Hanchuan Aier are located in county-level cities, and a total of 3 ophthalmology hospitals including Yuanling Aier
WuXi AppTec Reports Q2 Results
2023 Interim Report | More than half of profits come from wealth management products, BGI's “idle period”
Earn money by lying down
It soared by 120 billion US dollars overnight! Eli Lilly vs. Novo Nordisk, the battle for diet pills begins
It is only a matter of time before K drugs become the next generation medicine king. It is only a matter of time before they become the magic medicine for weight loss.
Yao Ming Kant “Cheer” on the Magic Medicine Express for Weight Loss | Insightful Research
CXO may not be as pessimistic as market expectations. On July 31, at a time when the entire pharmaceutical sector was being drastically adjusted, the CXO sector bucked the trend and rose throughout the day due to Kanglong Chemical's performance forecast. On the evening of the same day, Yao Ming Kangde released its 2023 semi-annual report, which seemed to give the CXO industry a little more confidence. CXO's leading performance was strong. Excluding COVID-19, 2023H1 is still growing fast. Pharmacomingkang's revenue was 18.871 billion yuan, up 6.3% year on year, excluding COVID-19 commercialization projects, up 27.9% year on year; net profit for the first half of the year was 5.313 billion yuan, up 14.6% year on year; adjusted N in the first half of the year
WuXi AppTec GAAP EPS of $1.07, Revenue of $9.91B Beats by $8.57B
Zhaoyan's new drug to “hoard monkeys roll over” has come to a standstill
The fried monkey rolled over. Recently, the 2023 semi-annual report of Zhaoyan New Drug (603127.SH) predicted a sharp decline in net profit. According to the performance forecast, the net profit of Zhaoyan New Drug in the first half of 2023 is expected to be 73 million yuan to 110 million yuan, with a year-on-year decline range of 70.40% to 80.40%. Excluding the net profit of 188 million yuan in the first quarter of 2023, Zhaoyan New Pharmaceutical already lost money in the second quarter, only about -115 million yuan to -078 million yuan. However, at the same time, there was no sharp decline in revenue from Zhaoyan New Pharmaceuticals. In the first half of 2023
Nvidia is leaving AI pharmaceuticals, are CXO companies expected to take off?
Performance implementation pending examination
WuXi AppTec GAAP EPS of RMB0.72, Revenue of RMB8.96B
WuXi AppTec Non-GAAP EPS of RMB3.18, Revenue of RMB39.35B
WuXi AppTec Reports Q3 Results
WuXi AppTec Non-GAAP EPS of RMB0.84, Revenue of RMB28.39B
Express News | Morgan Stanley: maintain Wuxi Apptec's "overweight" rating and target price of HK $177,
Sirona Biochem contracts China's WuXi AppTec to make anti-aging compound
Sirona Biochem (OTCPK:SRBCF) has contracted Shanghai-based WuXi AppTec (OTCPK:WUXAY) (OTCPK:WUXIF) for a small-scale production of TFC-1326, a compound being explored for anti-aging effects. Sirona sa